Absci corp ABSI.US 總覽分析
ABSI 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分較低，若以價值投資為目標，已經有長期投資部位可能需陸續減碼
ABSI 近期報酬表現
-7.67%
Absci corp
-3.92%
同產業平均
-0.77%
S&P500
與 ABSI 同產業的標的表現
- RXRX Recursion pharmaceuticals inc價值 3 分趨勢 2 分波段 2 分籌碼 4 分股利 1 分查看更多
ABSI 公司資訊
Absci Corporation is a data-first generative artificial intelligence (AI) drug creation company. The Company combines AI with scalable wet lab technologies to create biologics for patients. The Company's Integrated Drug Creation platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, its Integrated Drug Creation platform aims to engineer biologics. It is developing a diversified portfolio of programs with a focus on cytokine biology. It has three wholly owned internal pipeline programs focusing on cytokine biology, as well as several other undisclosed pipeline programs under evaluation. Its wholly owned pipeline programs include ABS-101, ABS-201, and ABS-301. The Company's other pipeline programs include ABS-501 and additional drug creation programs.